[en] BACKGROUND: It is not known whether drugs that block the renin-angiotensin system reduce the risk of diabetes and cardiovascular events in patients with impaired glucose tolerance. METHODS: In this double-blind, randomized clinical trial with a 2-by-2 factorial design, we assigned 9306 patients with impaired glucose tolerance and established cardiovascular disease or cardiovascular risk factors to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. We then followed the patients for a median of 5.0 years for the development of diabetes (6.5 years for vital status). We studied the effects of valsartan on the occurrence of three coprimary outcomes: the development of diabetes; an extended composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure, arterial revascularization, or hospitalization for unstable angina; and a core composite outcome that excluded unstable angina and revascularization. RESULTS: The cumulative incidence of diabetes was 33.1% in the valsartan group, as compared with 36.8% in the placebo group (hazard ratio in the valsartan group, 0.86; 95% confidence interval [CI], 0.80 to 0.92; P<0.001). Valsartan, as compared with placebo, did not significantly reduce the incidence of either the extended cardiovascular outcome (14.5% vs. 14.8%; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.43) or the core cardiovascular outcome (8.1% vs. 8.1%; hazard ratio, 0.99; 95% CI, 0.86 to 1.14; P=0.85). CONCLUSIONS: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events. (ClinicalTrials.gov number, NCT00097786.)
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Knowler, W.C., Bain, R.P., Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies (1997) Diabetes, 46, pp. 701-710
Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria (1999) Lancet, 354, pp. 617-621
Nathan, D.M., Davidson, M.B., Defronzo, R.A., Impaired fasting glucose and impaired glucose tolerance: Implications for care (2007) Diabetes Care, 30, pp. 753-759
Pan, X.R., Li, G.W., Hu, Y.H., Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: The Da Qing IGT and Diabetes Study (1997) Diabetes Care, 20, pp. 537-544
Tuomilehto, J., Lindström, J., Eriksson, J.G., Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance (2001) N Engl J Med, 344, pp. 1343-1350
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (2002) N Engl J Med, 346, pp. 393-403. , Diabetes Prevention Program Research Group
Bethel, M.A., Califf, R.M., Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease (2007) Am J Cardiol, 99, pp. 726-731
Gillies, C.L., Abrams, K.R., Lambert, P.C., Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: Systematic review and meta-analysis (2007) BMJ, 334, p. 299
Chiasson, J.L., Josse, R.G., Gomis, R., Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial (2002) Lancet, 359, pp. 2072-2077
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial (2006) Lancet, 368, pp. 1096-1105. , DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. [Erratum, Lancet 2006
368:1770.]
Yusuf, S., Gerstein, H., Hoogwerf, B., Ramipril and the development of diabetes (2001) JAMA, 286, pp. 1882-1885
Kjeldsen, S.E., Julius, S., Mancia, G., Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: The VALUE trial (2006) J Hypertens, 24, pp. 1405-1412
Yusuf, S., Ostergren, J.B., Gerstein, H.C., Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure (2005) Circulation, 112, pp. 48-53. , [Erratum, Circulation 2005:112(7):e292.]
Angiotensin- Converting-enzyme inhibition in stable coronary artery disease (2004) N Engl J Med, 351, pp. 2058-2068. , The PEACE Trial Investigators
Abuissa, H., Jones, P.G., Marso, S.P., O'Keefe Jr., J.H., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: A meta-analysis of randomized clinical trials (2005) J Am Coll Cardiol, 46, pp. 821-826
Effect of ramipril on the incidence of diabetes (2006) N Engl J Med, 355, pp. 1551-1562. , The DREAM Trial Investigators
Califf, R.M., Boolell, M., Haffner, S.M., Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial (2008) Am Heart J, 156, pp. 623-632
Effect of nateglinide on the incidence of diabetes and cardiovascular events (2010) N Engl J Med, , The NAVIGATOR Study Group. DOI: 10.1056/NEJMoa1001122
Bethel, M.A., Holman, R., Haffner, S.M., Determining the most appropriate components for a composite clinical trial outcome (2008) Am Heart J, 156, pp. 633-640
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Diabetes Care, 20, pp. 1183-1197
Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation (1998) Diabet Med, 15, pp. 539-553
Lan, K.K.G., Demets, D.L., Discrete sequential boundaries for clinical trials (1983) Biometrika, 70, pp. 659-663
Alberti, K.G., Zimmet, P., Shaw, J., The metabolic syndrome - A new worldwide definition (2005) Lancet, 366, pp. 1059-1062. , IDF Epidemiology Task Force Consensus Group
Murthy, K., Stevens, L.A., Stark, P.C., Levey, A.S., Variation in the serum creatinine assay calibration: A practical application to glomerular filtration rate estimation (2005) Kidney Int, 68, pp. 1884-1887
Jandeleit-Dahm, K.A., Tikellis, C., Reid, C.M., Johnston, C.I., Cooper, M.E., Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes (2005) J Hypertens, 23, pp. 463-473
Ingelfinger, J.R., Solomon, C.G., Angiotensin- Converting-enzyme inhibitors for impaired glucose tolerance - Is there still hope? (2006) N Engl J Med, 355, pp. 1608-1610
Scheen, A.J., Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. 2. Overview of physiological and biochemical mechanisms (2004) Diabetes Metab, 30, pp. 498-505
Gress, T.W., Nieto, F.J., Shahar, E., Wofford, M.R., Brancati, F.L., Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus (2000) N Engl J Med, 342, pp. 905-912
Barzilay, J.I., Davis, B.R., Cutler, J.A., Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2006) Arch Intern Med, 166, pp. 2191-2201
Elliott, W.J., Meyer, P.M., Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis (2007) Lancet, 369, pp. 201-207. , [Erratum, Lancet 2007
369:1518.]
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients (2000) N Engl J Med, 342, pp. 145-153. , Prevention Evaluation Study Investigators. [Errata, N Engl J Med 2000
342:748, 1376.]
Fox, K.M., Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) (2003) Lancet, 362, pp. 782-788. , EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Yusuf, S., Teo, K., Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial (2008) Lancet, 372, pp. 1174-1183. , Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, [Erratum, Lancet 2008
372:1384.]
Ilanne-Parikka, P., Eriksson, J.G., Lindström, J., Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study (2008) Diabetes Care, 31, pp. 805-807
Li, G., Zhang, P., Wang, J., The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow- Up study (2008) Lancet, 371, pp. 1783-1789
Cohn, J.N., Tognoni, G., A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure (2001) N Engl J Med, 345, pp. 1667-1675
Pfeffer, M.A., McMurray, J.J.V., Velazquez, E.J., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both (2003) N Engl J Med, 349, pp. 1893-1906. , [Erratum, N Engl J Med 2004
